Skip to main content
Top
Published in: International Cancer Conference Journal 2/2023

19-12-2022 | Metastasis | Mini-review

Liver metastases of a neuroendocrine tumor arising from a tailgut cyst treated with interventional locoregional therapies: a case report and review of the literature on recurrent cases

Authors: Kosuke Fujimoto, Fumikazu Koyama, Hiroyuki Kuge, Shinsaku Obara, Yosuke Iwasa, Takeshi Takei, Tadataka Takagi, Tomomi Sadamitsu, Suzuka Harada, Tomoko Uchiyama, Chiho Ohbayashi, Hideyuki Nishiofuku, Toshihiro Tanaka, Masayuki Sho

Published in: International Cancer Conference Journal | Issue 2/2023

Login to get access

Abstract

A tailgut cyst is a rare, developmental cyst occurring in the presacral space. Although primarily benign, malignant transformation is a possible complication. Herein, we report a case of liver metastases after resection of a neuroendocrine tumor (NET) arising from a tailgut cyst. A 53-year-old woman underwent surgery for a presacral cystic lesion with nodules in the cyst wall. The tumor was diagnosed as a Grade 2 NET arising from a tailgut cyst. Thirty-eight months after surgery, multiple liver metastases were identified. The liver metastases were controlled with transcatheter arterial embolization and ablation therapy. The patient has survived for 51 months after the recurrence. Several NETs derived from tailgut cysts have been previously reported. According to our literature review, the proportion of Grade 2 tumors in NETs derived from tailgut cysts was 38.5%, and four of the 5 cases of Grade 2 NETs (80%) relapsed, while all eight cases of Grade 1 NETs did not relapse. Grade 2 NET may be a high-risk group for recurrence in NETs arising from tailgut cysts. The percentage of Grade 2 NETs in tailgut cysts was higher than that of rectal NETs, but lower than that of midgut NETs. To the best of our knowledge, this is the first case of liver metastases of a neuroendocrine tumor arising from a tailgut cyst that was treated with interventional locoregional therapies, and the first report to describe about the degree of malignancy of neuroendocrine tumors originating from tailgut cysts in terms of the percentage of Grade 2 NETs.
Literature
7.
go back to reference Liang JJ, Alrawi S, Fuller GN, Tan D (2008) Carcinoid tumors arising in tailgut cysts may be associated with estrogen receptor status: case report and review of the literature. Int J Clin Exp Pathol 1:539–543PubMedPubMedCentral Liang JJ, Alrawi S, Fuller GN, Tan D (2008) Carcinoid tumors arising in tailgut cysts may be associated with estrogen receptor status: case report and review of the literature. Int J Clin Exp Pathol 1:539–543PubMedPubMedCentral
21.
go back to reference WHO Classification of Tumours Editorial Board (2019) Digestive system tumours, WHO classification of tumours, 5th edn. IARC Publications, Lyon WHO Classification of Tumours Editorial Board (2019) Digestive system tumours, WHO classification of tumours, 5th edn. IARC Publications, Lyon
32.
go back to reference Rinke A, Müller H-H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663. https://doi.org/10.1200/JCO.2009.22.8510CrossRefPubMed Rinke A, Müller H-H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663. https://​doi.​org/​10.​1200/​JCO.​2009.​22.​8510CrossRefPubMed
Metadata
Title
Liver metastases of a neuroendocrine tumor arising from a tailgut cyst treated with interventional locoregional therapies: a case report and review of the literature on recurrent cases
Authors
Kosuke Fujimoto
Fumikazu Koyama
Hiroyuki Kuge
Shinsaku Obara
Yosuke Iwasa
Takeshi Takei
Tadataka Takagi
Tomomi Sadamitsu
Suzuka Harada
Tomoko Uchiyama
Chiho Ohbayashi
Hideyuki Nishiofuku
Toshihiro Tanaka
Masayuki Sho
Publication date
19-12-2022
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal / Issue 2/2023
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-022-00587-2

Other articles of this Issue 2/2023

International Cancer Conference Journal 2/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine